Apotex Releases New Supply of Tamoxifen into Canadian Market
Dec 5, 2019Expedited Release Occurs Earlier Than Anticipated
December 5th, 2019, Toronto, Ontario - Canada’s leading generic drug manufacturer, Apotex, announced today that its first shipment of the drug tamoxifen has been released to the Canadian market. Additional releases are scheduled for December 2019 and January 2020.
Collaborating with Health Canada, Apotex expedited the return to market almost one month earlier than their latest projection.
“Our goal from the outset was to make the Canadian supply available as soon as possible to reduce the impact on patients,” said Jeff Watson, President & CEO, Apotex Inc. “We recognize the importance of this medication and that it can be unsettling for patients if it is in short supply. To facilitate a quicker re-entry to the market, we re-prioritized production of our portfolio, and were able to produce this faster than we normally would,” said Watson.
Indeed, Apotex had initially projected a release by the end of January and was then able to advance that deadline to December 31st, 2019. With additional pressure on the manufacturing teams, they were able to accelerate this date to an even earlier time.
“There’s no doubt that being a Canadian-based manufacturer and having a flexible supply chain were key enablers in us achieving this goal,” said Mr. Watson.
###
Jordan Berman
Global Director, Corporate Communications
Apotex Inc.
Direct: 416-401-7487
Mobile: 647-272-2287
Email
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Nov 17, 2026
Apotex launches APO-LINAGLIPTIN™, expanding access to treatment options for Canadians living with type 2 diabetes
TORONTO, ON, November 16, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), the largest Canadian-based global health company, today announced the launch of APO-LINAGLIPTIN™ (linagliptin tablets), the latest addition to its portfolio of medicines.
-
Nov 12, 2026
Apotex Announces Second Quarter 2027 Results
TORONTO, ON, November 12, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), a Canadian-based global health company and Canada’s largest pharmaceutical company, today announced its financial and operating results for the three and six months ended September 30, 2026. All financial figures are in Canadian dollars unless otherwise indicated.
-
Oct 9, 2026
Apotex to announce second quarter fiscal 2027 financial results and host conference call on Nov. 12, 2026
TORONTO, Oct. 8, 2026 /CNW/ -- Apotex Health Corp.("Apotex") (TSX: APTX) today announced that it will issue a press release with its second quarter Fiscal 2027 financial results on Thursday, November 12, 2026, at approximately 6:00 a.m. ET. Apotex will host a conference call and live webcast to discuss the results at 8:00a.m. ET.